Dr Claire Ives (Senior MSL Director) and Dr Fernando Osorio (MSL Director) will together head Pharmanovia’s influential Medical Science Liaison (MSL) team. Dr Claire Ives will head Oncology and Cardiology and Dr Fernando Osorio Endocrinology and Neurology
UK – The lifecycle management company, Pharmanovia has made two instrumental additions to its Scientific Affairs team with the appointment of Dr Claire Ives and Dr Fernando Osorio, as it pushes ahead with its mission to enhance and revitalise iconic medicines across the globe.
Reporting directly to, and working alongside, Dr Stephen Deacon who joined as interim Chief Scientific Officer in May this year, Dr Ives will head the new Medical Science Liaison (MSL) Group covering Oncology and Cardiology treatment areas for all global medical science activities, while Dr Osorio will head Endocrinology and Neurology.
The appointments underpin Pharmanovia’s commitment to bolster its medical engagement activities, to develop and implement innovative solutions to address the unmet needs of healthcare professionals and patients globally.
Dr Osorio, a certified orthopaedic surgeon by the Spanish Ministry of Health, has over 15 years’ experience in the pharmaceutical industry, having held positions across medical affairs, clinical development and strategic management. Prior to joining Pharmanovia, Dr Osorio held roles at MSD, Novo Nordisk, Servier, and Biogen.
A General Medical Council (GMC) registered UK medical physician and a former GP with significant experience in medical affairs, Dr Ives has worked with several world-leading pharmaceutical businesses including Novartis, Vifor Pharma, Chiesi, and Novo Nordisk, bringing invaluable expertise of international market nuances to Pharmanovia.
Dr James Burt, CEO of Pharmanovia, comments: “Claire and Fernando’s appointments are further proof of Pharmanovia’s deep-rooted commitment to establishing a world-leading Medical Science Liaison team, which can identify and engage with global, regional, and local experts to gain insight that will be crucial in helping us create new ways to make today’s medicines relevant for tomorrow. We are all incredibly excited to welcome Claire and Fernando to Pharmanovia and I am very much looking forward to working with them.”
Dr Claire Ives says: “Joining Pharmanovia at such an exciting point within the organisation’s strategic growth journey is incredibly exciting. Supporting clinical research and real-world evidence generation is fundamental to a thriving, responsible, and patient-centred pharmaceutical business. I am delighted to take on a key role within such a rapidly evolving organisation.”
Dr Fernando Osorio adds: “Pharmanovia is an organisation that continues to go from strength to strength and solidify its position as a leader within value-added medicines. I am therefore delighted to be taking on this role within the Medical Affairs team as part of Pharmanovia’s mission to support the delivery of essential medicines to patients. Establishing strong connections with healthcare professionals to understand their patients’ needs is vital to developing novel solutions that will significantly improve the end-patient experience, and I look forward to collaborating with the wider organisation to carve out a path to achieving this.”
For further information, please contact:
Alison Dyson, Director of Communications, Pharmanovia
Phone +44 (0) 7442 256310 / Email Alison.email@example.com
The PHA Group